The study conducted by a team of researchers from Johnson and Johnson, looked at previously existing research, carried out between December 2019 and August 2020 for Covid and from January 2020 to June 2021 for long Covid, which evaluated the effects of COVID-19 on 1.3 million people.
Published in Current Medical Research and Opinion, the study is among the first to assess the specific health conditions that take place as an outcome of coronavirus-related illness by gender.
According to the study authors, “Knowledge about fundamental sex differences underpinning the clinical manifestations, disease progression, and health outcomes of Covid- 19 is crucial for the identification of effective therapies. Differences in immune system between females and males could be an important driver of sex differences in long Covid.”
“Females mount more rapid and robust immune responses, which can protect them from initial infection.
“However, this same difference can render females vulnerable to prolonged autoimmune-related diseases,” they added.